Proteomics and metabolomics in inflammatory bowel disease

Yunki Yau, Rupert W. Leong, Ming Zeng, Valerie C. Wasinger*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)


Genome-wide studies in inflammatory bowel disease (IBD) have allowed us to understand Crohn's disease and ulcerative colitis as forms of related autoinflammatory disorders that arise from a multitude of pathogenic origins. Proteomics and metabolomics are the offspring of genomics that possess unprecedented possibilities to characterize unknown pathogenic pathways. It has been about a decade since proteomics was first applied to IBD, and 5 years for metabolomics. These techniques have yielded novel and potentially important findings, but turning these results into beneficial patient outcomes remains challenging. This review recounts the history and context of clinical IBD developments before and after proteomics and metabolomics IBD in this field, discusses the challenges in consolidating high complexity data with physiological understanding, and provides an outlook on the emerging principles that will help interface the bioanalytical laboratory with IBD prognosis.

Original languageEnglish
Pages (from-to)1076-1086
Number of pages11
JournalJournal of Gastroenterology and Hepatology (Australia)
Issue number7
Publication statusPublished - 2013
Externally publishedYes


  • Crohn's disease
  • Inflammatory bowel disease
  • Mass spectrometry
  • Metabolomics
  • Proteomics
  • Ulcerative colitis


Dive into the research topics of 'Proteomics and metabolomics in inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this